Revvity, Inc.
RVTY Healthcare · Diagnostics & ResearchFairly valued.
Fairly Valued (Neutral) — Filing.fyi's reading derived from the latest 10-K and forensic scores.
The four readings.
What the filing actually says.
Revvity’s 2025 10-K begins its Management’s Discussion and Analysis (MD&A) with a prominent disclaimer regarding forward-looking statements — statements about future events or financial performance, often with caveats. The company explicitly notes that “any statements contained in this report that are not statements of historical fact may be deemed to be forward-looking statements.” This framing sets the stage for the entire discussion, immediately directing the reader to consider the inherent uncertainties in financial projections. The MD&A further advises that “actual results may differ materially” from these forward-looking statements, pointing to “Risk Factors” in Item 1A for details.
The forensic scores offer a mixed but generally stable picture. Beneish’s 1999 eight-ratio earnings-manipulation detector, the M-Score, registers at -2.4615, which is below the -1.78 threshold, suggesting lower risk of earnings manipulation. Altman’s Z″ — a 1968 bankruptcy-distress index — comes in at 2.46, placing Revvity in the 1.10–2.60 “grey zone,” indicating neither clear financial distress nor robust safety. Piotroski’s F-Score, a 9-point fundamental strength scan, stands at 6.0, a respectable score that does not flag significant operational weakness.
The MD&A’s opening serves as a crucial pedagogical moment, highlighting the distinction between historical fact and future expectation. The company’s emphasis that actual results may differ materially from its plans, intentions, or expectations is a standard but vital disclosure. It underscores the importance of reviewing the “Risk Factors” in Item 1A, which the MD&A explicitly references for the specific factors that could cause such divergences. While the excerpt for Item 1A is largely structural, its presence as a dedicated section for these material factors is consistent with the MD&A’s cautionary tone.
This filing, through its forensic scores and MD&A framing, provides a snapshot of Revvity’s financial health and disclosure practices. The Fog Index — readability score; 12 = newspaper, 18+ = obfuscatory — of 14.98 suggests the document is reasonably accessible, not intentionally obscured. However, this reading cannot predict market movements or establish a definitive valuation. It merely interprets the company’s self-reported financial posture and the clarity with which it communicates its outlook.
Filing timeline
- May 5, 20268-KMaterial event (2026-05-05)### Item 2.02 of Form 8-K (including Exhibit 99 .1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange0Read →
- May 1, 20268-KMaterial event (2026-04-28)### Item 5.03 Amendments to Articles of Organization or Bylaws; Change in Fiscal Year At the annual meeting of shareholders of Revvity, Inc . (the “Company”) he0Read →
- Mar 16, 2026DEF 14AProxy statement (2026-04-28)0Read →
- Feb 24, 202610-KAnnual report (2025-12-28)Period: 2025-12-280Read →
- Feb 2, 20268-KMaterial event (2026-02-02)### Item 2.02 shall be deemed to be furnished, and not filed . SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has0Read →
- Nov 4, 202510-QQuarterly report (2025-09-28)Period: 2025-09-280Read →
If this case caught your eye
Financial Shenanigans
Schilit's framework for the seven shenanigan types is the standard reference for the kind of MD&A pattern-matching this site does.
View on Amazon →The Interpretation of Financial Statements
The original — and still the clearest — explanation of why working-capital trends matter more than headline earnings.
View on Amazon →Quality of Earnings
Out of print, expensive, worth it. The chapter on receivables-vs-revenue divergence applies almost word-for-word to most distressed filings.
View on Amazon →